PTEN loss correlates with T cell exclusion across human cancers

Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer

(2020) Romualdo Barroso-Sousa et al.   CLINICAL CANCER RESEARCH

B cells and tertiary lymphoid structures promote immunotherapy response

(2020) Beth A. Helmink et al.   NATURE

WNT/β-catenin pathway activation correlates with immune exclusion across human cancers

(2019) Jason J. Luke et al.   CLINICAL CANCER RESEARCH

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

(2019) Junfei Zhao et al.   NATURE MEDICINE

Targeting the PI3-kinase pathway in triple-negative breast cancer

(2019) J Pascual et al.   ANNALS OF ONCOLOGY

PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells

(2019) Thiago Vidotto et al.   PROSTATE

Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma

(2019) Weiyi Peng et al.   CLINICAL CANCER RESEARCH

PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer

(2019) Chao Wang et al.   FASEB JOURNAL

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer

(2019) Nicolas Guibert et al.   LUNG CANCER

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

(2019) Jonathan A. Trujillo et al.   Journal for ImmunoTherapy of Cancer

Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms

(2018) Marco Bezzi et al.   NATURE MEDICINE

The functions and regulation of the PTEN tumour suppressor: new modes and prospects

(2018) Yu-Ru Lee et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic Mechanisms of Immune Evasion in Colorectal Cancer

(2018) Catherine S. Grasso et al.   Cancer Discovery

PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance

(2018) Luke Russell et al.   Nature Communications

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma

(2017) Suzanne George et al.   IMMUNITY

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Immunotherapy for Unresectable Stage III Non–Small-Cell Lung Cancer

(2017) Naiyer A. Rizvi et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

(2017) Zhong-Yi Dong et al.   OncoImmunology

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers

(2016) Marie-Caroline Dieu-Nosjean et al.   IMMUNOLOGICAL REVIEWS

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

(2016) P.-L. Chen et al.   Cancer Discovery

Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer

(2016) R. F. Sweis et al.   Cancer Immunology Research

Alternative preprocessing of RNA-Sequencing data in The Cancer Genome Atlas leads to improved analysis results

(2015) Mumtahena Rahman et al.   BIOINFORMATICS

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

Enhancing Chemotherapy Efficacy in Pten -Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity

(2014) Alberto Toso et al.   Cell Reports

Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State

(2012) Isabel Garcia-Cao et al.   CELL

The functions and regulation of the PTEN tumour suppressor

(2012) Min Sup Song et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB–Cytokine Network

(2011) Haoqiang Ying et al.   Cancer Discovery

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

(2011) Craig H Mermel et al.   GENOME BIOLOGY

Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma

(2010) James S. Waldron et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Tenets of PTEN Tumor Suppression

(2008) Leonardo Salmena et al.   CELL

Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

(2008) Shidong Jia et al.   NATURE

The role of PTEN signaling perturbations in cancer and in targeted therapy

(2008) M Keniry et al.   ONCOGENE

Understanding PTEN regulation: PIP2, polarity and protein stability

(2008) N R Leslie et al.   ONCOGENE